BioAtla, Inc. (BCAB)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioAtla, Inc. (BCAB) trades at $3.60 with AI Score 50/100 (Grade B). BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing conditionally active biologic (CAB) antibody-based therapeutics for solid tumor cancer. Market cap: $4.54M, Sector: Healthcare.
Last analyzed: May 10, 2026Analyst Coverage for BCAB: BCAB does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BCAB against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BCAB: the 4 perspectives are evenly split. Dominant signal: Seth Klarman bearish.
BioAtla, Inc. (BCAB) Healthcare & Pipeline Overview
BioAtla, Inc. is a clinical-stage biopharmaceutical company specializing in conditionally active biologic (CAB) antibody-drug conjugates for solid tumor cancers. Their pipeline includes BA3011, BA3021, and BA3071, targeting cancers such as NSCLC, melanoma, and ovarian cancer, positioning them within the competitive oncology therapeutics market.
What Is the Investment Thesis for BCAB?
BioAtla presents a high-risk, high-reward investment profile typical of clinical-stage biopharmaceutical companies. The company's CAB technology offers a potentially differentiated approach to cancer therapy, with the goal of reducing systemic toxicity. Key value drivers include the clinical progress of BA3011, BA3021, and BA3071, particularly in pivotal trials. Successful clinical trial outcomes and potential regulatory approvals could significantly increase the company's valuation. The company's high gross margin of 100.0% suggests strong potential profitability if products reach commercialization. However, the company's negative profit margin of -2980.3% reflects substantial ongoing R&D expenses. Investors should closely monitor clinical trial data, regulatory milestones, and the company's cash runway.
Based on FMP financials and quantitative analysis
BCAB Key Highlights
- Market capitalization of $0.01 billion, reflecting its position as a small-cap biopharmaceutical company.
- Gross margin of 100.0%, indicating efficient cost management in product manufacturing.
- Profit margin of -2980.3%, highlighting significant ongoing research and development expenses typical of clinical-stage companies.
- Lead product candidate BA3011 targets multiple solid tumor types, including soft tissue sarcoma and NSCLC.
- Beta of 1.21, suggesting higher volatility compared to the overall market.
Who Are BCAB's Competitors?
BCAB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $119.99 | -0.64% | $296.35B | 64 |
| PFE Pfizer Inc. | $26.16 | -0.04% | $149.10B | 58 |
| NVS Novartis AG | $153.07 | -0.55% | 293B | 57 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.02 | +0.61% | $1.60B | 79 |
| ANAB AnaptysBio, Inc. | $54.24 | +4.11% | $2.34B | 79 |
| ABCL AbCellera Biologics Inc. | $5.23 | -0.76% | $1.60B | 76 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BCAB's Key Strengths?
- Novel CAB technology platform.
- Targeted approach to cancer therapy.
- Experienced management team.
- Strong intellectual property position.
What Are BCAB's Weaknesses?
- Clinical-stage company with no approved products.
- High R&D expenses and negative profit margin.
- Reliance on clinical trial success.
- Limited financial resources.
What Could Drive BCAB Stock Higher?
- Data readouts from ongoing clinical trials of BA3011 in soft tissue sarcoma and NSCLC (projected Q4 2026).
- Initiation of Phase 3 trials for BA3011 pending positive Phase 2 results (projected H1 2027).
- Advancement of BA3021 and BA3071 through Phase 1/2 clinical trials.
- Potential for new strategic partnerships and collaborations.
What Are the Key Risks for BCAB?
- Clinical trial failures or delays.
- Competition from established pharmaceutical companies with more resources.
- Regulatory hurdles and delays in obtaining approvals.
- High R&D expenses and cash burn rate.
- Dependence on successful development and commercialization of its product candidates.
What Are the Growth Opportunities for BCAB?
- Expansion of BA3011 into additional indications: BioAtla has the opportunity to expand the use of BA3011 beyond its current targets of soft tissue sarcoma, NSCLC, and ovarian cancer. Exploring its efficacy in other solid tumors could significantly increase its market potential. The global market for soft tissue sarcoma treatment is projected to reach $1.5 billion by 2028, while the NSCLC market is expected to exceed $30 billion. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
- Advancement of BA3021 and BA3071 through clinical trials: The successful development and commercialization of BA3021 and BA3071 represent significant growth opportunities. BA3021 targets multiple solid tumor types, including melanoma, while BA3071 is a CAB anti-CTLA-4 antibody. The global market for melanoma treatment is projected to reach $10 billion by 2027. Timeline: Phase 1/2 trials ongoing with potential for Phase 3 initiation in 2027-2028.
- Strategic partnerships and collaborations: BioAtla can leverage strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and global distribution networks. The value of oncology-focused partnerships can range from upfront payments of $50 million to potential milestone payments exceeding $1 billion. Timeline: Ongoing discussions with potential partners, with potential deals announced in the next 12-18 months.
- Expansion into new therapeutic areas: While currently focused on oncology, BioAtla's CAB technology could be applied to other therapeutic areas, such as autoimmune diseases or inflammatory conditions. Exploring these new applications could diversify the company's pipeline and reduce its reliance on oncology. The global market for autoimmune disease treatments is projected to reach $150 billion by 2028. Timeline: Preclinical research ongoing with potential for new program initiation in 2027-2028.
- Geographic expansion into international markets: BioAtla can expand its commercial reach by entering international markets, particularly in Europe and Asia. These markets offer significant growth potential, driven by increasing healthcare spending and aging populations. The oncology market in Asia is projected to grow at a CAGR of 10% over the next five years. Timeline: Potential for initial market entry in Europe and Asia within the next 3-5 years, pending regulatory approvals.
What Opportunities Does BCAB Have?
- Expansion into new therapeutic areas.
- Strategic partnerships with larger pharmaceutical companies.
- Positive clinical trial results.
- Regulatory approvals for its product candidates.
What Threats Does BCAB Face?
- Clinical trial failures.
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Patent challenges.
What Are BCAB's Competitive Advantages?
- Proprietary Conditionally Active Biologics (CAB) technology platform.
- Strong intellectual property portfolio protecting its CABs and ADCs.
- Clinical-stage pipeline with multiple product candidates in development.
- Experienced management team with expertise in antibody engineering and oncology.
What Does BCAB Do?
BioAtla, Inc., founded in 2007 and headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on developing a novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's core technology centers around Conditionally Active Biologics (CABs), which are designed to be active in the tumor microenvironment while minimizing off-target effects on healthy tissues. BioAtla's lead product candidate, BA3011, is a CAB antibody-drug conjugate (ADC) targeting soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. In addition to BA3011, BioAtla is developing BA3021, a CAB ADC targeting multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer. The company is also advancing BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla's pipeline reflects its commitment to addressing unmet needs in oncology by developing targeted therapies with improved safety profiles.
What Products and Services Does BCAB Offer?
- Develops Conditionally Active Biologics (CABs) for cancer treatment.
- Creates antibody-drug conjugates (ADCs) targeting solid tumors.
- Designs therapies that are active in the tumor microenvironment.
- Minimizes off-target effects on healthy tissues.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Focuses on specific and selective antibody-based therapeutics.
How Does BCAB Make Money?
- Develops and patents novel CAB-based therapeutics.
- Out-licenses or co-develops its product candidates with pharmaceutical partners.
- Generates revenue through milestone payments and royalties on product sales.
- Funds research and development through venture capital and public offerings.
What Industry Does BCAB Operate In?
BioAtla operates within the competitive biotechnology industry, specifically focusing on oncology therapeutics. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in personalized medicine. The company's CAB technology positions it within the targeted therapy segment, competing with other companies developing antibody-drug conjugates and immunotherapies. The industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Success hinges on demonstrating clinical efficacy and safety, securing regulatory approvals, and establishing commercial partnerships.
Who Are BCAB's Key Customers?
- Patients with solid tumor cancers, including NSCLC, melanoma, and ovarian cancer.
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Healthcare providers who prescribe cancer therapies.
BCAB Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in BioAtla's future prospects, indicating that those closest to the company believe in its potential growth.
- The company has received positive feedback on its innovative therapies, which are gaining traction in the oncology space and attracting attention from the medical community.
- Social sentiment has shown a growing interest in BioAtla's pipeline, reflecting optimism among retail investors and traders about upcoming clinical trials.
- Collaborations with larger pharmaceutical firms have been highlighted, suggesting that BioAtla is positioning itself well within the competitive landscape.
Bear Case
- Concerns about the company's ability to deliver results from its clinical trials have surfaced, leading to skepticism among some investors regarding its future performance.
- Recent market volatility has affected sentiment, with many traders adopting a cautious stance towards biotech stocks, including BioAtla.
- There have been mixed reviews from analysts on the sustainability of BioAtla's growth, contributing to uncertainty about its long-term viability.
- Social media discussions indicate a faction of investors worried about potential dilution from future funding rounds, which could impact shareholder value.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BCAB Latest News
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Apr 27, 2026
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Apr 15, 2026
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Apr 1, 2026
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Mar 10, 2026
BCAB Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCAB.
Price Targets
Wall Street price target analysis for BCAB.
BCAB MoonshotScore
What does this score mean?
The MoonshotScore rates BCAB's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Leadership: Jay Short
CEO
Jay Short is the CEO of BioAtla, Inc. His background includes extensive experience in the biotechnology industry, with a focus on drug discovery and development. He has held leadership positions in several biotech companies, overseeing research and development programs. His expertise spans antibody engineering, protein therapeutics, and oncology. He has a strong track record of advancing novel therapies through preclinical and clinical development.
Track Record: Under Jay Short's leadership, BioAtla has advanced multiple CAB-based product candidates into clinical trials, including BA3011, BA3021, and BA3071. He has overseen the expansion of the company's intellectual property portfolio and the establishment of strategic partnerships. His strategic decisions have focused on prioritizing clinical development programs and securing funding to support the company's growth.
Common Questions About BCAB (Healthcare)
What does BioAtla, Inc. do?
BioAtla, Inc. is a clinical-stage biopharmaceutical company that specializes in developing Conditionally Active Biologics (CABs) for the treatment of solid tumor cancers. Their innovative CAB technology allows for the creation of antibody-based therapeutics that are specifically activated in the tumor microenvironment, minimizing off-target effects on healthy tissues. The company's pipeline includes several product candidates, such as BA3011, BA3021, and BA3071, which target a range of solid tumors, including non-small cell lung cancer (NSCLC), melanoma, and ovarian cancer. BioAtla's business model revolves around developing and patenting these novel CAB-based therapeutics, with the goal of out-licensing or co-developing them with larger pharmaceutical partners.
What are the main risks for BCAB?
BioAtla faces several key risks inherent to clinical-stage biopharmaceutical companies. Clinical trial failures or delays represent a significant risk, as the company's pipeline is dependent on positive clinical outcomes. Competition from established pharmaceutical companies with greater resources and approved products poses a threat. Regulatory hurdles and delays in obtaining approvals could impede the commercialization of its product candidates. The company's high R&D expenses and cash burn rate necessitate careful financial management. Ultimately, BioAtla's success depends on the successful development and commercialization of its product candidates, which is subject to considerable uncertainty.
What are the key factors to evaluate for BCAB?
BioAtla, Inc. (BCAB) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does BCAB data refresh on this page?
BCAB prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BCAB's recent stock price performance?
BioAtla, Inc. (BCAB) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel CAB technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BCAB overvalued or undervalued right now?
Valuing BioAtla, Inc. (BCAB) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying BCAB?
Before investing in BioAtla, Inc. (BCAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BCAB to a portfolio?
Key strength of BioAtla, Inc. (BCAB): Novel CAB technology platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The company is a clinical-stage biopharmaceutical company, and its future success is dependent on clinical trial outcomes and regulatory approvals.